Table 3 Comprehensive list of PD-L1 inhibitors and PD-1 inhibitors with antibody class and immune adverse events. This table shows the similarities and differences between PD-1/PD-L1 inhibitors
From: Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Target | Drugs | Antibody class | Immune-related adverse events |
|---|---|---|---|
PD-L1 | Atezolizumab | IgG1 | Pneumonitis, hepatitis, colitis, endocrinopathies (thyroid disease, adrenal insufficiency, hypophysitis, type 1 diabetes), meningitis/encephalitis, pancreatitis, dermatitis/rash |
Durvalumab | IgG1 | Pneumonitis, hepatitis, colitis, endocrinopathies (thyroid disease, adrenal insufficiency, hypophysitis, type 1 diabetes), nephritis | |
Avelumab | IgG1 | Pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, renal dysfunction | |
Envafolimab | IgG1 | Increased aspartate aminotransferase, increased alanine aminotransferase, lymphopenia | |
BMS-936559 | IgG4 | Hypothyroidism, hepatitis, sarcoidosis, endophthalmitis, diabetes mellitus, myasthenia gravis | |
CK-301 | IgG1 | N/A (ongoing) | |
CS-1001 | IgG4 | Anemia, increased blood bilirubin, protein urine present, white blood cell count decreased, proteinuria | |
SHR-1316 | IgG4 | N/A (ongoing) | |
CBT-502 | IgG1 | N/A (ongoing) | |
BGB-A333 | IgG1 variant | N/A (ongoing) | |
PD-1 | Nivolumab | IgG4 | Pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, renal dysfunction, encephalitis, rash |
Pembrolizumab | IgG4 | Pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, renal dysfunction | |
Cemiplimab | IgG4 | Cellulitis, pneumonitis, hypercalcemia, pleural effusion |